Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

2020; Elsevier BV; Volume: 329; Linguagem: Inglês

10.1016/j.jconrel.2020.10.009

1873-4995

Fábio Rocha Formiga, Roger LeBlanc, Juliana de Souza Rebouças, Leonardo Paiva Farias, Ronaldo N. de Oliveira, Lindomar Pena,

Parasitic Diseases Research and Treatment

Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.